GSDME孔形成与功能调控的结构与机制见解
Structural and Mechanistic Insights Into GSDME Pore Formation and Functional Regulation.
文献信息
| PMID | 42848328 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Fei Mo |
| 作者单位 | Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, China. |
| 期刊 | FASEB journal : official publication of the Federation of American Societies for Experimental Biology |
| SCI 分区 | Q1 |
| IF | 4.7 |
| 研究类型 | 基础研究 · 基础/转化 |
| 所属专科 | 耳科 |
中文摘要
Gasdermin E(GSDME)是gasdermin家族中一个独特的成员,与耳聋、癌症和神经退行性疾病相关,并介导化疗诱导的细胞焦亡;然而,其成孔机制仍知之甚少。在此,我们展示了GSDME孔的冷冻电镜结构,其寡聚化学计量范围为23至29个原体。通过诱变、脂质体渗漏试验和癌症相关突变分析,我们确定了负责膜结合、浅层膜插入以及通过三个不同结构界面进行寡聚化的关键残基。分子动力学模拟揭示了动态脂质招募和特异性:阴离子TMCL2被碱性残基选择性招募以促进浅层膜穿透,而两性离子DPhPC溶剂化极性蛋白区域。在组装的25聚体孔内,特定脂质作为结构稳定剂以增强分子间氢键网络。我们的发现支持GSDME孔组装背后的逐步、时间依赖性机制。这项研究为GSDME功能提供了关键的机制见解,并可能指导针对癌症和神经退行性疾病的靶向治疗开发。
英文摘要
Gasdermin E (GSDME) is a unique member of the gasdermin family linked to deafness, cancer, and neurodegenerative diseases, and mediates chemotherapy-induced pyroptosis; however, its pore-forming mechanism remains poorly understood. Here, we present cryo-EM structures of GSDME pores with oligomeric stoichiometries ranging from 23 to 29 protomers. Using mutagenesis, liposome leakage assays, and analysis of cancer-associated mutations, we identified key residues responsible for membrane binding, shallow membrane insertion, and oligomerization through three distinct structural interfaces. Molecular dynamics simulations reveal dynamic lipid recruitment and specificity: Anionic TMCL2 is selectively recruited by basic residues to facilitate shallow membrane penetration, while zwitterionic DPhPC solvates polar protein regions. Within the assembled 25-mer pore, specific lipids act as structural stabilizers to reinforce the intermolecular hydrogen bond network. Our findings support a stepwise, time-dependent mechanism underlying GSDME pore assembly. This study provides critical mechanistic insights into GSDME function and may guide the development of targeted therapeutics for cancers and neurodegenerative diseases.